Novel radiosensitizing anticancer therapeutics

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2487-2500

  Linkous, Amanda G ^a   Yazlovitskaya, Eugenia M ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cancer stem cells; Radiation resistance; Radioprotectors; Radiosensitizers; Review

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ALDEHYDE DEHYDROGENASE; ALKYLATING AGENT; AMIFOSTINE; ARACHIDONYLTRIFLUOROMETHYL KETONE; AUTOTAXIN; BENZALDEHYDE DERIVATIVE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYTOSOLIC PHOSPHOLIPASE A2; DIETHYLAMINOBENZALDEHYDE; FIGITUMUMAB; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; METHYLARACHIDONYL FLUOROPHOSPHONATE; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHONIC ACID DERIVATIVE; PROTEIN MDM2; PYRIDOXAMINE; RADIOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

CANCER CONTROL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; DRUG TARGETING; HUMAN; IONIZING RADIATION; METASTASIS INHIBITION; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION PROTECTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION-SENSITIZING AGENTS;

EID: 84865685861     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Brunner TB, Kunz-Schughart LA, Grosse-Gehling P and Baumann M: Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol 22: 151-174, 2012.
2. Aref A and Berri R: Role of Radiation Therapy in the Management of Locally Advanced Pancreatic Cancer. J Clin Oncol 30: 1564-1564, 2012.
3. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M and Laheru D: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27: 1806-1813, 2009.
4. Desgrandchamps F: Recurrence following radiotherapy. Front Radiat Ther Oncol 41: 86-92, 2008.
5. Zielske SP, Spalding AC, Wicha MS and Lawrence TS: Ablation of breast cancer stem cells with radiation. Transl Oncol 4: 227-233, 2011.
6. Impicciatore G, Sancilio S, Miscia S and Di Pietro R: Nutlins and ionizing radiation in cancer therapy. Curr Pharm Des 16: 1427-1442, 2010.
7. Deng X, Yin X, Allan R, Lu DD, Maurer CW, Haimovitz-Friedman A, Fuks Z, Shaham S and Kolesnick R: Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans. Science 322: 110-115, 2008.
8. Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z and Kolesnick RN: Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 180: 525-535, 1994. (Pubitemid 24224129)
9. Kolesnick R and Fuks Z: Radiation and ceramide-induced apoptosis. Oncogene 22: 5897-5906, 2003. (Pubitemid 37176710)
10. Edwards E, Geng L, Tan J, Onishko H, Donnelly E and Hallahan DE: Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 62: 4671-4677, 2002.
11. Tan J and Hallahan DE: Growth factor-independent activation of protein kinase B contributes to the inherent resistance of vascular endothelium to radiation-induced apoptotic response. Cancer Res 63: 7663-7667, 2003. (Pubitemid 37466693)
12. Linkous A, Geng L, Lyshchik A, Hallahan DE and Yazlovitskaya EM: Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Clin Cancer Res 15: 1635-1644, 2009.
13. Schulte RR, Linkous AG, Hallahan DE and Yazlovitskaya EM: Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer. Cancer Lett 304: 137-143, 2011.
14. Yazlovitskaya EM, Linkous AG, Thotala DK, Cuneo KC and Hallahan DE: Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium. Cell Death Differ 15: 1641-1653, 2008.
15. Chakraborti S: Phospholipase A(2) isoforms: a perspective. Cell Signal 15: 637-665, 2003.
16. Linkous AG, Yazlovitskaya EM and Hallahan DE: Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst 102: 1398-1412, 2010.
17. Bonventre JV: The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. J Am Soc Nephrol 10: 404-412, 1999.
18. Fujita Y, Yoshizumi M, Izawa Y, Ali N, Ohnishi H, Kanematsu Y, Ishizawa K, Tsuchiya K and Tamaki T: Transactivation of fetal liver kinase-1/kinase- insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation. Endocrinology 147: 1377-1385, 2006. (Pubitemid 43244372)
19. Prokazova NV, Zvezdina ND and Korotaeva AA: Effect of lysophosphatidylcholine on transmembrane signal transduction. Biochemistry (Mosc) 63: 31-37, 1998. (Pubitemid 128588473)
20. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K and Fukuzawa K: Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277: 39436-39442, 2002. (Pubitemid 35190918)
21. Xie Y and Meier KE: Lysophospholipase D and its role in LPA production. Cell Signal 16: 975-981, 2004.
22. Yang Y, Mou L, Liu N and Tsao MS: Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21: 216-222, 1999. (Pubitemid 129502219)
23. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T and Arai H: Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 281: 17492-17500, 2006.
24. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J and Mills GB: Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582: 257-264, 2002. (Pubitemid 34634137)
25. Tokumura A, Kume T, Fukuzawa K, Tahara M, Tasaka K, Aoki J, Arai H, Yasuda K and Kanzaki H: Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity. Life sciences 80: 1641-1649, 2007. (Pubitemid 46441268)
26. Ptaszynska MM, Pendrak ML, Stracke ML and Roberts DD: Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res 8: 309-321, 2008.
27. Schleicher SM, Thotala DK, Linkous AG, Hu R, Leahy KM, Yazlovitskaya EM and Hallahan DE: Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS One 6: e22182, 2011.
28. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J and Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281: 25822-25830, 2006. (Pubitemid 44401970)
29. Tokumura A, Miyake M, Yoshimoto O, Shimizu M and Fukuzawa K: Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma. Lipids 33: 1009-1015, 1998. (Pubitemid 28516479)
30. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J and Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227-233, 2002.
31. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, Fells JI, Perygin D, Parrill AL, Tigyi G and Prestwich GD: Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 69: 5441-5449, 2009.
32. Linkous A, Hallahan D and Yazlovitskaya E: Autotaxin and lysophosphatidic acid receptors as novel targets for the radiosensitization of tumor vasculature in non-small cell lung cancer. Curr Angiogenesis 1: 72-80, 2012.
33. Valenciano A, Henriquez-Hernandez LA, Moreno M, Lloret M and Lara PC: Role of IGF-1 receptor in radiation response. Transl Oncol 5: 1-9, 2012.
34. Tezuka M, Watanabe H, Nakamura S, Yu D, Aung W, Sasaki T, Shibuya H and Miura M: Antiapoptotic activity is dispensable for insulin-like growth factor I receptor-mediated clonogenic radioresistance after gamma-irradiation. Clin Cancer Res 7: 3206-3214, 2001. (Pubitemid 32963845)
35. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L, Burgaud JL, Carter D, Baserga R and Glazer PM: Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57: 3079-3083, 1997. (Pubitemid 27351714)
36. Baserga R: The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55: 249-252, 1995.
37. Bartucci M, Morelli C, Mauro L, Ando S and Surmacz E: Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 61: 6747-6754, 2001. (Pubitemid 32896497)
38. Lloret M, Lara PC, Bordon E, Pinar B, Rey A, Falcon O, Molano F and Hernandez MA: IGF-1R expression in localized cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol 106: 8-11, 2007. (Pubitemid 46901080)
39. Yuan Y, Zhou X, Song J, Qiu X, Li J, Ye L, Meng X and Xia D: Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 117: 192-200, 2008. (Pubitemid 351415354)
40. Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L, Lewensohn R and Dricu A: Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett 222: 173-181, 2005. (Pubitemid 40603644)
41. Riesterer O, Yang Q, Raju U, Torres M, Molkentine D, Patel N, Valdecanas D, Milas L and Ang KK: Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers. Int J Radiat Oncol Biol Phys 79: 1179-1187, 2011.
42. Iwasa T, Okamoto I, Suzuki M, Hatashita E, Yamada Y, Fukuoka M, Ono K and Nakagawa K: Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 15: 5117-5125, 2009.
43. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002. (Pubitemid 34074005)
44. Crawford L: Human p53 and human tumours. Bioessays 3: 117-120, 1985.
45. Crawford LV, Pim DC and Lamb P: The cellular protein p53 in human tumours. Mol Biol Med 2: 261-272, 1984. (Pubitemid 16257494)
46. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
47. Vousden KH: Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602: 47-59, 2002.
48. Vousden KH and Lu X: Live or let die: The cell's response to p53. Nat Rev Cancer 2: 594-604, 2002. (Pubitemid 37328926)
49. Hollstein M and Hainaut P: Massively regulated genes: The example of TP53. J Pathol 220: 164-173, 2010.
50. Blattner C: Regulation of p53: Size matters. Cell Cycle 11: 1270, 2012.
51. Blattner C: Regulation of p53: the next generation. Cell Cycle 7: 3149-3153, 2008.
52. Momand J, Wu HH and Dasgupta G: MDM2 - master regulator of the p53 tumor suppressor protein. Gene 242: 15-29, 2000. (Pubitemid 30064488)
53. Shangary S and Wang S: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241, 2009.
54. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997. (Pubitemid 27220766)
55. Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem 67: 425-479, 1998. (Pubitemid 28411135)
56. Maki CG: Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem 274: 16531-16535, 1999.
57. Wu X, Bayle JH, Olson D and Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993. (Pubitemid 23207405)
58. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr., Vogelstein B and Kastan MB: Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91: 2684-2688, 1994. (Pubitemid 24139412)
59. Perry ME, Piette J, Zawadzki JA, Harvey D and Levine AJ: The MDM-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 90: 11623-11627, 1993. (Pubitemid 24008691)
60. Freedman DA and Levine AJ: Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18: 7288-7293, 1998. (Pubitemid 28533048)
61. Tao W and Levine AJ: Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96: 3077-3080, 1999. (Pubitemid 29148846)
62. Cao C, Shinohara ET, Subhawong TK, Geng L, Woon Kim K, Albert JM, Hallahan DE and Lu B: Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther 5: 411-417, 2006.
63. Supiot S, Hill RP and Bristow RG: Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 7: 993-999, 2008. (Pubitemid 351551053)
64. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N and Liu EA: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848, 2004. (Pubitemid 38174664)
65. Vassilev LT: Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3: 419-421, 2004.
66. Arya AK, El-Fert A, Devling T, Eccles RM, Aslam MA, Rubbi CP, Vlatkovic N, Fenwick J, Lloyd BH, Sibson DR, Jones TM and Boyd MT: Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br J Cancer 103: 186-195, 2010.
67. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH and Terrian DM: A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 6: 595-605, 2007. (Pubitemid 46440434)
68. LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB and Mayo LD: Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res 67: 450-454, 2007. (Pubitemid 46192180)
69. Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, Albini A and Zauli G: Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res 100: 61-69, 2007. (Pubitemid 46066774)
70. Secchiero P, di Iasio MG, Gonelli A and Zauli G: The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 14: 2100-2110, 2008.
71. Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM and Perry ME: MDM2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462-472, 2003.
72. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA and Perry ME: Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev 20: 16-21, 2006. (Pubitemid 43042663)
73. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339-9344, 2006.
74. Diehn M and Clarke MF: Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 98: 1755-1757, 2006. (Pubitemid 46017927)
75. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006. (Pubitemid 44949604)
76. Blazek ER, Foutch JL and Maki G: Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133-cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67: 1-5, 2007. (Pubitemid 44959518)
77. Kristiansen G, Sammar M and Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35: 255-262, 2004. (Pubitemid 40585311)
78. Sagiv E and Arber N: The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy. Expert Rev Gastroenterol Hepatol 2: 125-133, 2008.
79. Schabath H, Runz S, Joumaa S and Altevogt P: CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119: 314-325, 2006. (Pubitemid 43210700)
80. Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG and Brunner TB: Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 75: 1216-1225, 2009.
81. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825-2837, 2004. (Pubitemid 38638845)
82. Castedo M, Perfettini JL, Roumier T and Kroemer G: Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 9: 1287-1293, 2002. (Pubitemid 36097698)
83. Ianzini F, Bertoldo A, Kosmacek EA, Phillips SL and Mackey MA: Lack of p53 function promotes radiation-induced mitotic catastrophe in mouse embryonic fibroblast cells. Cancer Cell Int 6: 11, 2006.
84. Hornsby PJ: Senescence as an anticancer mechanism. J Clin Oncol 25: 1852-1857, 2007.
85. Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL and Lee JS: PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 18: 666-677, 2011.
86. Roninson IB: Tumor cell senescence in cancer treatment. Cancer Res 63: 2705-2715, 2003.
87. Brown JM and Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5: 231-237, 2005. (Pubitemid 40314954)
88. Jackson B, Brocker C, Thompson DC, Black W, Vasiliou K, Nebert DW and Vasiliou V: Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 5: 283-303, 2011.
89. Ma I and Allan AL: The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7: 292-306, 2011.
90. Alison MR, Guppy NJ, Lim SM and Nicholson LJ: Finding cancer stem cells: Are aldehyde dehydrogenases fit for purpose? J Pathol 222: 335-344, 2010.
91. Douville J, Beaulieu R and Balicki D: ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18: 17-25, 2009.
92. Croker AK and Allan AL: Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res Treat 133: 75-87, 2011.
93. Evers P, Lee PP, DeMarco J, Agazaryan N, Sayre JW, Selch M and Pajonk F: Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer 10: 384, 2010.
94. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G and Zitvogel L: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059, 2007. (Pubitemid 47517504)
95. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L and Formenti SC: Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58: 862-870, 2004. (Pubitemid 38221143)
96. Lee Y, Auh SL, Wang Y, Burnette B, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR and Fu YX: Therapeutic effects of ablative radiation on local tumor require CD8+ T-cells: changing strategies for cancer treatment. Blood 114: 589-595, 2009.
97. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG and Lord EM: Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180: 3132-3139, 2008.
98. Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, Smyth MJ, Kroemer G and Zitvogel L: Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 22: 113-124, 2010.
99. Meng Y, Efimova EV, Hamzeh KW, Darga TE, Mauceri HJ, Fu YX, Kron SJ and Weichselbaum RR: Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. Mol Ther 20: 1046-1055, 2012.
100. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P and Neefjes JJ: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203: 1259-1271, 2006. (Pubitemid 43736595)
101. Shiao SL and Coussens LM: The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 15: 411-421, 2010.
102. Bhide SA and Nutting CM: Advances in radiotherapy for head and neck cancer. Oral Oncol 46: 439-441, 2010.
103. Gudkov AV and Komarova EA: Radioprotection: Smart games with death. J Clin Invest 120: 2270-2273, 2010.
104. Weiss JF and Landauer MR: Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 189: 1-20, 2003. (Pubitemid 36725020)
105. Denekamp J: Cell kinetics and radiation biology. Int J Radiat Biol Relat Stud Phys Chem Med 49: 357-380, 1986.
106. Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, Ramsey MR, Jin J, Wong KK, Su L, Zhou D and Sharpless NE: Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 120: 2528-2536, 2010.
107. Yazlovitskaya EM, Edwards E, Thotala D, Fu A, Osusky KL, Whetsell WO Jr., Boone B, Shinohara ET and Hallahan DE: Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation. Cancer Res 66: 11179-11186, 2006. (Pubitemid 46009945)
108. Thotala DK, Hallahan DE and Yazlovitskaya EM: Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res 68: 5859-5868, 2008.
109. Thotala DK, Hallahan DE and Yazlovitskaya EM: Glycogen synthase kinase 3beta inhibitors protect hippocampal neurons from radiation-induced apoptosis by regulating MDM2-p53 pathway. Cell Death Differ 19: 387-396, 2012.
110. Thotala DK, Geng L, Dickey AK, Hallahan DE and Yazlovitskaya EM: A new class of molecular targeted radioprotectors: GSK-3beta inhibitors. Int J Radiat Oncol Biol Phys 76: 557-565, 2010.
111. Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P and Yazlovitskaya E: Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis. Free Rad Biol Med 47: 779-785, 2009.
112. Williams ME: New potential agents in treating diabetic kidney disease: the fourth act. Drugs 66: 2287-2298, 2006.
113. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK and Lewis JB: Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 23: 131-136, 2012.
114. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ and McGill JB: Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 27: 605-614, 2007 (Pubitemid 350014947)